Legal Representation
Attorney
J. Christopher Lynch
USPTO Deadlines
Application History
23 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 18, 2011 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 18, 2011 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 14, 2011 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 13, 2011 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 13, 2011 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 15, 2010 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 15, 2010 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 15, 2010 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 20, 2010 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 20, 2010 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 12, 2010 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 12, 2010 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Mar 10, 2010 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Mar 10, 2010 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 10, 2010 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 16, 2010 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 30, 2009 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 30, 2009 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 30, 2009 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 19, 2009 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 19, 2009 | MPMK | O | NOTICE OF PSEUDO MARK MAILED | Loading... |
| Aug 18, 2009 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
| Aug 18, 2009 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for medical or veterinary purposes, namely, pharmaceutical preparations for the treatment or mediation of injury to humans or animals caused by inappropriate or excessive activation of the innate immune system
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Pharmaceutical drug development services
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
X-IN EIGHT
Classification
International Classes
005
042